| Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer Y Imamura, T Mukohara, Y Shimono, Y Funakoshi, N Chayahara, ... Oncology reports 33 (4), 1837-1843, 2015 | 830 | 2015 |
| Lenvatinib for anaplastic thyroid cancer M Tahara, N Kiyota, T Yamazaki, N Chayahara, K Nakano, L Inagaki, ... Frontiers in oncology 7, 25, 2017 | 180 | 2017 |
| A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer S Takahashi, N Kiyota, T Yamazaki, N Chayahara, K Nakano, L Inagaki, ... Future Oncology 15 (7), 717-726, 2019 | 124 | 2019 |
| Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin H Goto, Y Shimono, Y Funakoshi, Y Imamura, M Toyoda, N Kiyota, ... Oncogene 38 (6), 767-779, 2019 | 109 | 2019 |
| Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer Y Fujiwara, T Kobayashi, N Chayahara, Y Imamura, M Toyoda, N Kiyota, ... PloS one 9 (11), e113259, 2014 | 58 | 2014 |
| Immunotherapy for squamous cell carcinoma of the head and neck T Yokota, A Homma, N Kiyota, M Tahara, N Hanai, T Asakage, ... Japanese Journal of Clinical Oncology 50 (10), 1089-1096, 2020 | 48 | 2020 |
| Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (PTS) with all histologic subtypes of advanced thyroid cancer (differentiated … S Takahashi, M Tahara, N Kiyota, T Yamazaki, N Chayahara, K Nakano, ... Annals of Oncology 25, iv343, 2014 | 41 | 2014 |
| Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer C Suzuki, N Kiyota, Y Imamura, H Goto, H Suto, N Chayahara, M Toyoda, ... Head & Neck 41 (9), 3023-3032, 2019 | 36 | 2019 |
| Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results. S Takahashi, N Kiyota, T Yamazaki, N Chayahara, K Nakano, L Inagaki, ... Journal of Clinical Oncology 34 (15_suppl), 6088-6088, 2016 | 30 | 2016 |
| Validity of new methods to evaluate renal function in cancer patients treated with cisplatin Y Funakoshi, Y Fujiwara, N Kiyota, T Mukohara, T Shimada, M Toyoda, ... Cancer Chemotherapy and Pharmacology 77, 281-288, 2016 | 29 | 2016 |
| Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide S Kimbara, Y Fujiwara, M Toyoda, N Chayahara, Y Imamura, N Kiyota, ... Clinical Journal of Gastroenterology 7, 255-259, 2014 | 24 | 2014 |
| Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate Y Funakoshi, Y Fujiwara, N Kiyota, T Mukohara, T Shimada, M Toyoda, ... Japanese journal of clinical oncology 43 (3), 271-277, 2013 | 23 | 2013 |
| Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer Y Funakoshi, K Yakushijin, G Ohji, W Hojo, H Sakai, R Takai, T Nose, ... Journal of Infection and Chemotherapy 28 (4), 516-520, 2022 | 21 | 2022 |
| Surgical outcomes of metastatic bone tumors in the extremities (Surgical outcomes of bone metastases) H Hara, Y Sakai, T Kawamoto, N Fukase, Y Kawakami, T Takemori, ... Journal of Bone Oncology 27, 100352, 2021 | 20 | 2021 |
| The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced … M Nishimura, M Toyoda, K Takenaka, Y Imamura, N Chayahara, N Kiyota, ... Cancer chemotherapy and pharmacology 77, 1165-1170, 2016 | 20 | 2016 |
| Systemic therapy for salivary gland malignancy: current status and future perspectives Y Imamura, N Kiyota, M Tahara, N Hanai, T Asakage, K Matsuura, I Ota, ... Japanese Journal of Clinical Oncology 52 (4), 293-302, 2022 | 18 | 2022 |
| Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck S Okano, A Homma, N Kiyota, M Tahara, N Hanai, T Asakage, K Matsuura, ... Japanese journal of clinical oncology 51 (2), 173-179, 2021 | 17 | 2021 |
| Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer C Suzuki, N Kiyota, Y Imamura, J Rikitake, S Sai, T Koyama, Y Hyogo, ... International Journal of Clinical Oncology 25, 1270-1277, 2020 | 16 | 2020 |
| Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging M Nishimura, M Hayashi, Y Mizutani, K Takenaka, Y Imamura, ... Oncotarget 9 (26), 18540, 2018 | 15 | 2018 |
| Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients Y Fujiwara, M Toyoda, N Chayahara, N Kiyota, T Shimada, Y Imamura, ... Plos one 9 (8), e104215, 2014 | 14 | 2014 |
